Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

This study tests a combination of anlotinib (a targeted anti-cancer drug), doxorubicin (chemotherapy), and radiation therapy as a pre-surgery (neoadjuvant) treatment for patients with high-grade soft tissue sarcoma — aggressive cancers of the body's connective tissues like muscle, fat, or vessels. The goal is to shrink tumors before surgery. **You may be eligible if...** - You are 18–75 years old with histologically confirmed high-grade soft tissue sarcoma (Grade 2–3) - Your sarcoma is a type that responds to chemotherapy (e.g., synovial sarcoma, leiomyosarcoma, liposarcoma) - Your cancer can potentially be surgically removed after treatment - You have at least one measurable lesion and are fit for radiation - Your blood counts and organ function are adequate **You may NOT be eligible if...** - Your sarcoma type does not respond to the planned treatments - You cannot tolerate surgery, radiation, or chemotherapy - You have another concurrent cancer - You are pregnant or breastfeeding - Your organ function is inadequate Talk to your doctor to see if this trial is right for you.